Chiromics, Bristol-Myers, GlaxoSmithKline deal

Chiromics announced separate deals with the pharmas to discover small molecules against undisclosed targets. Bristol-Myers will receive a non-exclusive license to Chiromics' chemical compound library and an exclusive license to a proprietary compound collection. Using its Chalis hit recognition algorithm, Chiromics will also discover and optimize compounds in its libraries against targets provided by Bristol-Myers. Bristol-Myers and Chiromics did not disclose additional details, while GlaxoSmithKline could not be reached. ...